25 XP   0   0   10

Hunan Er Kang Pharmaceutical
Buy, Hold or Sell?

Let's analyse Hunan Er Kang Pharmaceutical together

PenkeI guess you are interested in Hunan Er Kang Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hunan Er Kang Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hunan Er Kang Pharmaceutical

I send you an email if I find something interesting about Hunan Er Kang Pharmaceutical.

Quick analysis of Hunan Er Kang Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Hunan Er Kang Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
94.9%

What is your share worth?

Current worth
¥2.46
Expected worth in 1 year
¥2.46
How sure are you?
79.5%

+ What do you gain per year?

Total Gains per Share
¥0.04
Return On Investment
1.4%

For what price can you sell your share?

Current Price per Share
¥2.70
Expected price per share
¥2.08 - ¥3.0218
How sure are you?
50%

1. Valuation of Hunan Er Kang Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥2.70

Intrinsic Value Per Share

¥-3.26 - ¥-3.91

Total Value Per Share

¥-0.80 - ¥-1.46

2. Growth of Hunan Er Kang Pharmaceutical (5 min.)




Is Hunan Er Kang Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?$701.2m$685m$15.9m2.3%

How much money is Hunan Er Kang Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money$1.7m-$31.5m$33.2m1,940.4%
Net Profit Margin2.2%-34.1%--

How much money comes from the company's main activities?

3. Financial Health of Hunan Er Kang Pharmaceutical (5 min.)




What can you expect buying and holding a share of Hunan Er Kang Pharmaceutical? (5 min.)

Welcome investor! Hunan Er Kang Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Hunan Er Kang Pharmaceutical.

What can you expect buying and holding a share of Hunan Er Kang Pharmaceutical?

First you should know what it really means to hold a share of Hunan Er Kang Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Hunan Er Kang Pharmaceutical is ¥2.7. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hunan Er Kang Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hunan Er Kang Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥2.46. Based on the TTM, the Book Value Change Per Share is ¥0.00 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hunan Er Kang Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.000.0%0.000.0%-0.02-0.6%0.000.0%0.000.2%
Usd Book Value Change Per Share0.00-0.1%0.000.0%-0.01-0.5%0.00-0.1%0.010.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.1%
Usd Total Gains Per Share0.00-0.1%0.000.0%-0.01-0.5%0.000.0%0.010.3%
Usd Price Per Share0.47-0.47-0.54-0.59-1.89-
Price to Earnings Ratio-147.18-44.46-146.88-44.22-78.72-
Price-to-Total Gains Ratio-256.71-296.47-174.48-99.69-237.48-
Price to Book Ratio1.38-1.38-1.62-1.61-11.92-
Price-to-Total Gains Ratio-256.71-296.47-174.48-99.69-237.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.37368
Number of shares2676
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (2676 shares)3.40-3.49
Gains per Year (2676 shares)13.59-13.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1131411-25-24
22521822-50-38
33833233-75-52
45134644-100-66
56446055-125-80
67657466-150-94
78968877-175-108
8102710288-200-122
9114811699-225-136
101279130110-250-150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%16.03.00.084.2%35.03.01.089.7%44.03.01.091.7%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%10.09.00.052.6%29.010.00.074.4%37.011.00.077.1%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%19.00.00.0100.0%37.00.02.094.9%44.00.04.091.7%
Total Gains per Share2.02.00.050.0%8.04.00.066.7%12.07.00.063.2%31.08.00.079.5%39.09.00.081.3%

Fundamentals of Hunan Er Kang Pharmaceutical

About Hunan Er Kang Pharmaceutical

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.

Fundamental data was last updated by Penke on 2024-03-25 23:26:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Hunan Er Kang Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hunan Er Kang Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -3.0% means that ¥-0.03 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is -3.0%. The company is making a loss. -1
  • The TTM is 2.2%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-3.0%TTM2.2%-5.2%
TTM2.2%YOY-34.1%+36.3%
TTM2.2%5Y-2.0%+4.1%
5Y-2.0%10Y12.1%-14.1%
1.1.2. Return on Assets

Shows how efficient Hunan Er Kang Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.2% Return on Assets means that Hunan Er Kang Pharmaceutical generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is -0.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.2%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM0.2%-0.4%
TTM0.2%YOY-4.2%+4.4%
TTM0.2%5Y-0.4%+0.6%
5Y-0.4%10Y1.7%-2.1%
1.1.3. Return on Equity

Shows how efficient Hunan Er Kang Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.2% Return on Equity means Hunan Er Kang Pharmaceutical generated ¥0.00 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is -0.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM0.2%-0.5%
TTM0.2%YOY-4.7%+4.9%
TTM0.2%5Y-0.5%+0.7%
5Y-0.5%10Y2.0%-2.5%

1.2. Operating Efficiency of Hunan Er Kang Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hunan Er Kang Pharmaceutical is operating .

  • Measures how much profit Hunan Er Kang Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.4%-1.4%
TTM1.4%YOY-2.1%+3.5%
TTM1.4%5Y3.9%-2.5%
5Y3.9%10Y1.9%+2.0%
1.2.2. Operating Ratio

Measures how efficient Hunan Er Kang Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.83 means that the operating costs are ¥1.83 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is 1.832. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.772. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.832TTM1.772+0.060
TTM1.772YOY1.833-0.061
TTM1.7725Y1.716+0.055
5Y1.71610Y1.109+0.607

1.3. Liquidity of Hunan Er Kang Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hunan Er Kang Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.36 means the company has ¥4.36 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is 4.364. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.851. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.364TTM3.851+0.513
TTM3.851YOY3.823+0.028
TTM3.8515Y5.183-1.331
5Y5.18310Y2.525+2.658
1.3.2. Quick Ratio

Measures if Hunan Er Kang Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.30 means the company can pay off ¥0.30 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is 0.302. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.414. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.302TTM0.414-0.113
TTM0.414YOY0.539-0.125
TTM0.4145Y0.786-0.371
5Y0.78610Y0.961-0.175

1.4. Solvency of Hunan Er Kang Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hunan Er Kang Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hunan Er Kang Pharmaceutical to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.08 means that Hunan Er Kang Pharmaceutical assets are financed with 8.3% credit (debt) and the remaining percentage (100% - 8.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is 0.083. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.102. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.083TTM0.102-0.019
TTM0.102YOY0.106-0.004
TTM0.1025Y0.102-0.001
5Y0.10210Y0.117-0.015
1.4.2. Debt to Equity Ratio

Measures if Hunan Er Kang Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 9.0% means that company has ¥0.09 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hunan Er Kang Pharmaceutical:

  • The MRQ is 0.090. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.114. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.090TTM0.114-0.024
TTM0.114YOY0.119-0.005
TTM0.1145Y0.115-0.002
5Y0.11510Y0.143-0.028

2. Market Valuation of Hunan Er Kang Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hunan Er Kang Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Hunan Er Kang Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -147.18 means the investor is paying ¥-147.18 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hunan Er Kang Pharmaceutical:

  • The EOD is -117.226. Based on the earnings, the company is expensive. -2
  • The MRQ is -147.184. Based on the earnings, the company is expensive. -2
  • The TTM is 44.458. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-117.226MRQ-147.184+29.958
MRQ-147.184TTM44.458-191.643
TTM44.458YOY146.876-102.418
TTM44.4585Y44.221+0.237
5Y44.22110Y78.719-34.498
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hunan Er Kang Pharmaceutical:

  • The EOD is -9.194. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.543. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 6.796. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-9.194MRQ-11.543+2.349
MRQ-11.543TTM6.796-18.339
TTM6.796YOY4.123+2.672
TTM6.7965Y-63.938+70.734
5Y-63.93810Y-70.971+7.033
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hunan Er Kang Pharmaceutical is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Hunan Er Kang Pharmaceutical:

  • The EOD is 1.099. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.380. Based on the equity, the company is underpriced. +1
  • The TTM is 1.380. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.099MRQ1.380-0.281
MRQ1.380TTM1.380+0.000
TTM1.380YOY1.624-0.245
TTM1.3805Y1.615-0.235
5Y1.61510Y11.918-10.303
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hunan Er Kang Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0130.001-2379%-0.097+621%-0.017+26%0.047-128%
Book Value Per Share--2.4572.456+0%2.400+2%2.644-7%2.230+10%
Current Ratio--4.3643.851+13%3.823+14%5.183-16%2.525+73%
Debt To Asset Ratio--0.0830.102-18%0.106-22%0.102-19%0.117-29%
Debt To Equity Ratio--0.0900.114-21%0.119-24%0.115-22%0.143-37%
Dividend Per Share--0.0000.009-98%0.001-71%0.007-97%0.013-98%
Eps---0.0060.006-196%-0.110+1818%-0.009+53%0.031-119%
Free Cash Flow Per Share---0.073-0.018-75%-0.012-83%-0.018-76%-0.028-61%
Free Cash Flow To Equity Per Share---0.073-0.049-33%-0.011-84%-0.024-68%0.012-702%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.974+3%
Intrinsic Value_10Y_max---3.915--------
Intrinsic Value_10Y_min---3.259--------
Intrinsic Value_1Y_max---0.081--------
Intrinsic Value_1Y_min---0.079--------
Intrinsic Value_3Y_max---0.481--------
Intrinsic Value_3Y_min---0.454--------
Intrinsic Value_5Y_max---1.166--------
Intrinsic Value_5Y_min---1.062--------
Market Cap5569019827.200-26%6992230509.3006987073997.125+0%8018376432.125-13%8857330943.482-21%28125996311.591-75%
Net Profit Margin---0.0300.022-240%-0.341+1036%-0.020-35%0.121-125%
Operating Margin---0.014-100%-0.0210%0.039-100%0.019-100%
Operating Ratio--1.8321.772+3%1.8330%1.716+7%1.109+65%
Pb Ratio1.099-26%1.3801.380+0%1.624-15%1.615-15%11.918-88%
Pe Ratio-117.226+20%-147.18444.458-431%146.876-200%44.221-433%78.719-287%
Price Per Share2.700-26%3.3903.388+0%3.888-13%4.278-21%13.628-75%
Price To Free Cash Flow Ratio-9.194+20%-11.5436.796-270%4.123-380%-63.938+454%-70.971+515%
Price To Total Gains Ratio-204.463+20%-256.714296.468-187%174.485-247%99.693-358%237.481-208%
Quick Ratio--0.3020.414-27%0.539-44%0.786-62%0.961-69%
Return On Assets---0.0020.002-198%-0.042+1852%-0.004+94%0.017-113%
Return On Equity---0.0020.002-196%-0.047+1911%-0.005+98%0.020-111%
Total Gains Per Share---0.0130.009-244%-0.096+627%-0.009-29%0.060-122%
Usd Book Value--701245558.199701032436.510+0%685099171.796+2%756910380.935-7%637633539.565+10%
Usd Book Value Change Per Share---0.0020.000-2379%-0.013+621%-0.002+26%0.007-128%
Usd Book Value Per Share--0.3400.340+0%0.332+2%0.366-7%0.309+10%
Usd Dividend Per Share--0.0000.001-98%0.000-71%0.001-97%0.002-98%
Usd Eps---0.0010.001-196%-0.015+1818%-0.001+53%0.004-119%
Usd Free Cash Flow---20959039.660-5159752.275-75%-3516461.135-83%-5065677.546-76%-7526410.640-64%
Usd Free Cash Flow Per Share---0.010-0.003-75%-0.002-83%-0.002-76%-0.004-61%
Usd Free Cash Flow To Equity Per Share---0.010-0.007-33%-0.002-84%-0.003-68%0.002-702%
Usd Market Cap770752344.084-26%967724702.487967011041.202+0%1109743298.206-13%1225854602.578-21%3892637889.524-75%
Usd Price Per Share0.374-26%0.4690.469+0%0.538-13%0.592-21%1.886-75%
Usd Profit---1643730.2481713366.950-196%-31533420.668+1818%-2488401.975+51%8862938.059-119%
Usd Revenue--54696520.40569148765.260-21%68209012.496-20%77779534.054-30%76346509.013-28%
Usd Total Gains Per Share---0.0020.001-244%-0.013+627%-0.001-29%0.008-122%
 EOD+3 -5MRQTTM+11 -24YOY+21 -135Y+12 -2310Y+10 -26

3.2. Fundamental Score

Let's check the fundamental score of Hunan Er Kang Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-117.226
Price to Book Ratio (EOD)Between0-11.099
Net Profit Margin (MRQ)Greater than0-0.030
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.302
Current Ratio (MRQ)Greater than14.364
Debt to Asset Ratio (MRQ)Less than10.083
Debt to Equity Ratio (MRQ)Less than10.090
Return on Equity (MRQ)Greater than0.15-0.002
Return on Assets (MRQ)Greater than0.05-0.002
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Hunan Er Kang Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.581
Ma 20Greater thanMa 502.618
Ma 50Greater thanMa 1002.667
Ma 100Greater thanMa 2003.025
OpenGreater thanClose2.740
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Net Income  6,2253,2219,44516,63426,079-20725,872-37,748-11,877
Net Income from Continuing Operations  3,1493,4486,59713,85920,45520820,663-37,820-17,156



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets5,524,397
Total Liabilities457,593
Total Stockholder Equity5,082,273
 As reported
Total Liabilities 457,593
Total Stockholder Equity+ 5,082,273
Total Assets = 5,524,397

Assets

Total Assets5,524,397
Total Current Assets1,694,958
Long-term Assets3,829,439
Total Current Assets
Cash And Cash Equivalents 501,645
Net Receivables 117,182
Inventory 731,119
Other Current Assets 150,983
Total Current Assets  (as reported)1,694,958
Total Current Assets  (calculated)1,500,929
+/- 194,029
Long-term Assets
Property Plant Equipment 2,953,142
Goodwill 10,008
Intangible Assets 384,880
Long-term Assets Other 45,997
Long-term Assets  (as reported)3,829,439
Long-term Assets  (calculated)3,394,027
+/- 435,412

Liabilities & Shareholders' Equity

Total Current Liabilities388,377
Long-term Liabilities69,217
Total Stockholder Equity5,082,273
Total Current Liabilities
Short Long Term Debt 149,000
Accounts payable 139,031
Other Current Liabilities 4,639
Total Current Liabilities  (as reported)388,377
Total Current Liabilities  (calculated)292,670
+/- 95,706
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,146
Long-term Liabilities  (as reported)69,217
Long-term Liabilities  (calculated)1,146
+/- 68,070
Total Stockholder Equity
Retained Earnings 1,782,764
Total Stockholder Equity (as reported)5,082,273
Total Stockholder Equity (calculated)1,782,764
+/- 3,299,509
Other
Capital Stock2,062,605
Common Stock Shares Outstanding 2,062,605
Net Invested Capital 5,231,273
Net Working Capital 1,306,581
Property Plant and Equipment Gross 2,953,142



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302010-12-312009-12-312008-12-31
> Total Assets 
122,377
185,730
295,773
371,834
1,133,657
1,128,171
1,235,781
1,214,946
1,208,621
1,237,592
1,281,825
1,331,959
1,350,304
1,447,001
1,572,246
1,766,487
1,826,545
2,220,554
2,390,374
2,946,570
3,136,033
4,801,355
4,894,306
5,000,758
5,179,479
5,653,241
6,230,959
6,425,693
6,233,715
5,720,068
5,782,852
5,906,735
6,040,087
6,197,671
6,247,467
6,185,884
6,143,769
6,554,792
6,876,562
6,663,558
6,546,796
6,824,009
6,500,574
6,398,766
5,431,979
5,462,015
5,555,125
5,698,662
5,855,659
5,600,338
5,584,757
5,524,397
5,524,3975,584,7575,600,3385,855,6595,698,6625,555,1255,462,0155,431,9796,398,7666,500,5746,824,0096,546,7966,663,5586,876,5626,554,7926,143,7696,185,8846,247,4676,197,6716,040,0875,906,7355,782,8525,720,0686,233,7156,425,6936,230,9595,653,2415,179,4795,000,7584,894,3064,801,3553,136,0332,946,5702,390,3742,220,5541,826,5451,766,4871,572,2461,447,0011,350,3041,331,9591,281,8251,237,5921,208,6211,214,9461,235,7811,128,1711,133,657371,834295,773185,730122,377
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,168,101
3,139,771
2,975,070
2,753,996
2,994,485
3,020,000
2,730,205
2,675,233
2,883,286
2,453,091
2,323,123
1,946,365
1,998,820
2,039,031
2,118,910
2,091,204
1,863,153
1,758,509
1,694,958
1,694,9581,758,5091,863,1532,091,2042,118,9102,039,0311,998,8201,946,3652,323,1232,453,0912,883,2862,675,2332,730,2053,020,0002,994,4852,753,9962,975,0703,139,7713,168,101000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,355,164
1,386,370
861,349
1,319,958
786,031
846,611
588,819
882,820
1,036,106
591,741
411,618
761,564
539,934
804,615
360,800
764,669
539,804
544,929
501,645
501,645544,929539,804764,669360,800804,615539,934761,564411,618591,7411,036,106882,820588,819846,611786,0311,319,958861,3491,386,3701,355,164000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
310,000
0
0
0
5,303
5,303
0
0
1,300
0
0
6,904
17,968
114,117
978
9,737
0
09,737978114,11717,9686,904001,300005,3035,303000310,00000000000000000000000000000000000000
       Net Receivables 
22,209
29,715
46,959
66,729
94,058
67,833
75,303
104,018
76,163
104,982
134,257
132,656
171,179
174,059
241,547
289,739
216,558
235,962
229,926
354,047
380,039
264,533
326,243
406,183
348,594
285,613
345,605
424,419
540,741
473,496
416,219
414,284
452,838
442,462
362,213
388,083
415,606
413,311
430,832
425,287
426,552
413,281
375,620
482,625
287,929
295,318
247,131
286,495
232,293
188,328
189,384
117,182
117,182189,384188,328232,293286,495247,131295,318287,929482,625375,620413,281426,552425,287430,832413,311415,606388,083362,213442,462452,838414,284416,219473,496540,741424,419345,605285,613348,594406,183326,243264,533380,039354,047229,926235,962216,558289,739241,547174,059171,179132,656134,257104,98276,163104,01875,30367,83394,05866,72946,95929,71522,209
       Other Current Assets 
3,191
13,599
5,185
6,807
5,640
20,600
40,806
15,427
30,641
58,196
48,139
53,980
81,060
65,325
65,528
56,366
93,106
55,541
48,894
81,519
141,801
85,939
980,880
204,547
409,335
218,668
295,376
176,212
533,317
136,283
657,478
176,794
622,007
100,098
70,298
86,990
137,334
828,012
193,924
683,360
204,499
648,539
176,527
635,194
182,100
395,244
150,382
546,589
158,781
280,627
123,791
150,983
150,983123,791280,627158,781546,589150,382395,244182,100635,194176,527648,539204,499683,360193,924828,012137,33486,99070,298100,098622,007176,794657,478136,283533,317176,212295,376218,668409,335204,547980,88085,939141,80181,51948,89455,54193,10656,36665,52865,32581,06053,98048,13958,19630,64115,42740,80620,6005,6406,8075,18513,5993,191
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,029,570
3,107,696
3,210,813
3,389,773
3,560,307
3,856,562
3,933,353
3,871,563
3,940,724
4,047,483
4,075,643
3,485,614
3,463,195
3,516,094
3,579,752
3,764,455
3,737,185
3,826,248
3,829,439
3,829,4393,826,2483,737,1853,764,4553,579,7523,516,0943,463,1953,485,6144,075,6434,047,4833,940,7243,871,5633,933,3533,856,5623,560,3073,389,7733,210,8133,107,6963,029,570000000000000000000000000000000000
       Property Plant Equipment 
51,906
62,891
123,480
140,582
125,077
166,941
216,089
224,028
264,460
345,149
352,975
384,227
379,977
509,238
574,348
645,249
797,919
996,611
1,155,264
1,242,576
1,310,390
1,474,606
1,702,272
1,832,837
2,066,157
2,540,777
2,638,072
2,666,314
2,625,039
2,579,324
2,538,556
2,562,190
2,590,176
2,617,308
2,613,639
2,706,097
2,713,651
2,794,632
2,905,122
2,997,046
2,957,643
3,002,870
3,080,414
3,110,884
2,604,403
2,597,751
2,658,190
2,729,056
2,856,547
2,814,042
2,919,569
2,953,142
2,953,1422,919,5692,814,0422,856,5472,729,0562,658,1902,597,7512,604,4033,110,8843,080,4143,002,8702,957,6432,997,0462,905,1222,794,6322,713,6512,706,0972,613,6392,617,3082,590,1762,562,1902,538,5562,579,3242,625,0392,666,3142,638,0722,540,7772,066,1571,832,8371,702,2721,474,6061,310,3901,242,5761,155,264996,611797,919645,249574,348509,238379,977384,227352,975345,149264,460224,028216,089166,941125,077140,582123,48062,89151,906
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,068
24,950
10,678
11,432
11,432
11,432
11,432
11,432
11,432
62,396
62,510
35,057
35,057
35,057
35,057
27,843
27,843
27,843
27,843
21,829
21,829
21,829
21,829
21,829
21,829
21,829
21,829
21,829
21,829
21,829
10,008
10,008
10,008
10,008
10,008
10,008
10,008
10,008
10,00810,00810,00810,00810,00810,00810,00810,00821,82921,82921,82921,82921,82921,82921,82921,82921,82921,82921,82927,84327,84327,84327,84335,05735,05735,05735,05762,51062,39611,43211,43211,43211,43211,43211,43210,67824,95023,06800000000000000
       Intangible Assets 
10,642
20,409
20,983
3,838
20,450
13,735
30,016
13,295
30,049
17,854
33,254
19,153
48,660
32,829
107,211
134,220
155,618
192,415
189,358
186,415
183,777
225,928
222,569
270,928
325,142
298,982
298,148
306,619
303,537
293,771
290,914
288,078
285,294
288,251
82,163
350,148
382,561
411,022
518,611
535,394
525,226
527,630
514,575
523,164
431,447
425,142
418,807
412,472
406,136
400,927
391,204
384,880
384,880391,204400,927406,136412,472418,807425,142431,447523,164514,575527,630525,226535,394518,611411,022382,561350,14882,163288,251285,294288,078290,914293,771303,537306,619298,148298,982325,142270,928222,569225,928183,777186,415189,358192,415155,618134,220107,21132,82948,66019,15333,25417,85430,04913,29530,01613,73520,4503,83820,98320,40910,642
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,933
4,122
821
17,938
65,715
88,877
3,028,874
46,879
75,980
63,509
53,622
20,090
16,450
21,044
25,671
29,333
64,451
64,428
45,997
45,99764,42864,45129,33325,67121,04416,45020,09053,62263,50975,98046,8793,028,87488,87765,71517,9388214,12216,933000000000000000000000000000000000
> Total Liabilities 
59,371
75,721
119,152
134,170
102,291
65,899
192,859
122,060
77,955
73,316
84,161
111,095
83,864
113,007
187,540
282,663
269,781
542,645
659,721
972,897
1,009,137
544,099
470,179
306,056
268,816
408,938
773,367
833,975
525,799
308,367
314,973
302,522
311,712
497,044
498,713
368,457
350,717
717,554
1,102,983
805,390
753,220
950,576
706,862
538,831
558,277
574,109
578,128
636,713
804,568
551,633
490,303
457,593
457,593490,303551,633804,568636,713578,128574,109558,277538,831706,862950,576753,220805,3901,102,983717,554350,717368,457498,713497,044311,712302,522314,973308,367525,799833,975773,367408,938268,816306,056470,179544,0991,009,137972,897659,721542,645269,781282,663187,540113,00783,864111,09584,16173,31677,955122,060192,85965,899102,291134,170119,15275,72159,371
   > Total Current Liabilities 
59,371
75,721
117,450
131,165
98,294
61,911
188,378
117,756
61,168
56,555
67,425
94,385
67,180
93,847
167,686
263,289
250,887
311,125
366,452
630,327
660,626
492,859
419,430
252,980
215,027
338,028
702,989
763,495
456,295
244,759
252,345
240,712
247,110
367,016
360,614
237,785
255,591
624,944
1,032,636
749,686
691,509
890,448
645,846
475,840
498,926
518,625
523,870
581,094
725,433
473,805
416,084
388,377
388,377416,084473,805725,433581,094523,870518,625498,926475,840645,846890,448691,509749,6861,032,636624,944255,591237,785360,614367,016247,110240,712252,345244,759456,295763,495702,989338,028215,027252,980419,430492,859660,626630,327366,452311,125250,887263,289167,68693,84767,18094,38567,42556,55561,168117,756188,37861,91198,294131,165117,45075,72159,371
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100,000
100,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000100,000100,000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100,000
100,000
0
0
340,000
748,000
463,000
463,000
663,000
396,000
246,000
246,000
272,750
286,919
297,794
396,641
199,000
149,000
149,000
149,000149,000199,000396,641297,794286,919272,750246,000246,000396,000663,000463,000463,000748,000340,00000100,000100,000000000000000000000000000000000000
       Accounts payable 
10,958
13,810
13,808
15,579
17,980
10,843
14,696
16,751
13,745
14,667
17,658
50,033
25,505
19,051
52,411
63,215
45,276
31,257
74,864
103,128
196,116
168,507
81,937
104,377
88,779
195,095
169,179
275,439
211,369
89,118
98,983
85,070
86,813
114,262
113,336
100,518
79,303
107,631
114,861
185,114
137,934
131,045
138,137
116,476
137,871
122,642
113,157
155,613
198,705
169,703
165,325
139,031
139,031165,325169,703198,705155,613113,157122,642137,871116,476138,137131,045137,934185,114114,861107,63179,303100,518113,336114,26286,81385,07098,98389,118211,369275,439169,179195,09588,779104,37781,937168,507196,116103,12874,86431,25745,27663,21552,41119,05125,50550,03317,65814,66713,74516,75114,69610,84317,98015,57913,80813,81010,958
       Other Current Liabilities 
23,413
23,911
43,642
47,586
58,314
51,068
113,682
41,005
47,423
41,888
49,767
44,352
41,675
74,796
112,275
107,073
94,111
120,257
116,719
119,203
108,006
129,545
143,657
148,603
126,249
142,933
257,838
217,081
244,926
155,641
153,362
155,642
160,297
0
0
123,319
139,239
157,925
143,913
83,208
66,446
82,363
87,235
97,197
80,563
106,544
97,321
109,493
104,572
90,067
78,092
4,639
4,63978,09290,067104,572109,49397,321106,54480,56397,19787,23582,36366,44683,208143,913157,925139,239123,31900160,297155,642153,362155,641244,926217,081257,838142,933126,249148,603143,657129,545108,006119,203116,719120,25794,111107,073112,27574,79641,67544,35249,76741,88847,42341,005113,68251,06858,31447,58643,64223,91123,413
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,029
138,099
130,672
95,127
92,610
70,347
55,703
61,710
60,128
61,016
62,991
59,351
55,485
54,258
55,618
79,135
77,828
74,219
69,217
69,21774,21977,82879,13555,61854,25855,48559,35162,99161,01660,12861,71055,70370,34792,61095,127130,672138,099130,029000000000000000000000000000000000
       Other Liabilities 
0
0
1,702
3,005
3,997
3,988
4,481
4,304
16,787
16,761
16,736
16,710
16,684
19,160
19,854
19,374
18,894
20,454
32,405
31,913
36,226
38,969
38,287
39,949
39,614
56,507
55,067
54,614
53,152
46,740
45,256
43,772
42,288
130,029
138,099
130,672
95,127
92,610
70,347
55,703
61,710
60,128
58,742
57,352
57,200
53,862
53,170
52,081
76,559
75,723
72,591
0
072,59175,72376,55952,08153,17053,86257,20057,35258,74260,12861,71055,70370,34792,61095,127130,672138,099130,02942,28843,77245,25646,74053,15254,61455,06756,50739,61439,94938,28738,96936,22631,91332,40520,45418,89419,37419,85419,16016,68416,71016,73616,76116,7874,3044,4813,9883,9973,0051,70200
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38
19
0
0
0
0
377
13,008
12,609
14,023
16,545
16,513
15,260
18,255
19,167
19,495
18,419
17,814
0
017,81418,41919,49519,16718,25515,26016,51316,54514,02312,60913,00837700001938000000000000000000000000000000000
> Total Stockholder Equity
61,024
108,764
175,228
235,696
1,029,205
1,059,812
1,040,257
1,089,732
1,124,281
1,157,793
1,191,090
1,214,088
1,259,503
1,326,747
1,361,538
1,441,227
1,499,680
1,621,723
1,671,743
1,897,113
2,050,495
4,183,663
4,352,773
4,625,881
4,844,154
5,182,607
5,400,374
5,544,617
5,661,967
5,366,690
5,425,886
5,562,171
5,685,851
5,662,476
5,711,062
5,780,912
5,758,878
5,800,712
5,739,913
5,825,163
5,766,463
5,842,289
5,764,354
5,834,085
4,851,211
4,869,042
4,970,458
5,058,358
5,050,821
5,054,292
5,104,552
5,082,273
5,082,2735,104,5525,054,2925,050,8215,058,3584,970,4584,869,0424,851,2115,834,0855,764,3545,842,2895,766,4635,825,1635,739,9135,800,7125,758,8785,780,9125,711,0625,662,4765,685,8515,562,1715,425,8865,366,6905,661,9675,544,6175,400,3745,182,6074,844,1544,625,8814,352,7734,183,6632,050,4951,897,1131,671,7431,621,7231,499,6801,441,2271,361,5381,326,7471,259,5031,214,0881,191,0901,157,7931,124,2811,089,7321,040,2571,059,8121,029,205235,696175,228108,76461,024
   Common Stock
5,000
88,210
138,000
138,000
184,000
184,000
184,000
239,200
239,200
239,200
239,200
239,200
239,200
239,200
454,480
454,480
454,480
454,480
908,960
911,946
911,947
1,028,361
1,028,361
2,056,722
2,060,361
2,060,361
2,060,361
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
2,062,605
0
02,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,062,6052,060,3612,060,3612,060,3612,056,7221,028,3611,028,361911,947911,946908,960454,480454,480454,480454,480239,200239,200239,200239,200239,200239,200239,200184,000184,000184,000138,000138,00088,2105,000
   Retained Earnings 
23,861
14,746
30,066
90,438
117,273
139,617
120,098
169,620
204,020
229,338
262,652
285,621
331,121
388,458
403,844
484,363
542,805
633,443
678,133
872,928
1,014,640
1,192,574
1,360,673
1,616,801
1,812,294
2,116,172
2,335,310
2,497,594
2,629,745
2,350,433
2,453,717
2,530,621
2,606,949
2,502,754
2,527,139
2,563,577
2,666,665
2,690,355
2,698,501
2,813,744
2,834,572
2,887,601
2,834,729
2,887,905
1,888,800
1,911,334
1,918,889
1,925,113
1,934,453
1,960,532
1,924,526
1,782,764
1,782,7641,924,5261,960,5321,934,4531,925,1131,918,8891,911,3341,888,8002,887,9052,834,7292,887,6012,834,5722,813,7442,698,5012,690,3552,666,6652,563,5772,527,1392,502,7542,606,9492,530,6212,453,7172,350,4332,629,7452,497,5942,335,3102,116,1721,812,2941,616,8011,360,6731,192,5741,014,640872,928678,133633,443542,805484,363403,844388,458331,121285,621262,652229,338204,020169,620120,098139,617117,27390,43830,06614,74623,861
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,362
56,564
89,975
73,274
91,418
90,416
32,623
-58,390
-44,197
-77,864
-69,910
-99,152
-105,650
-13,554
81,769
48,341
25,734
112,000
0
0112,00025,73448,34181,769-13,554-105,650-99,152-69,910-77,864-44,197-58,39032,62390,41691,41873,27489,97556,56432,362000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,998,519
Cost of Revenue-1,533,018
Gross Profit465,501465,501
 
Operating Income (+$)
Gross Profit465,501
Operating Expense-2,001,399
Operating Income-2,880-1,535,898
 
Operating Expense (+$)
Research Development56,566
Selling General Administrative228,053
Selling And Marketing Expenses-
Operating Expense2,001,399284,619
 
Net Interest Income (+$)
Interest Income833
Interest Expense-7,974
Other Finance Cost-8,329
Net Interest Income1,188
 
Pretax Income (+$)
Operating Income-2,880
Net Interest Income1,188
Other Non-Operating Income Expenses-
Income Before Tax (EBT)9,569-2,880
EBIT - interestExpense = -7,974
49,519
57,493
Interest Expense7,974
Earnings Before Interest and Taxes (EBIT)-17,543
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax9,569
Tax Provision--20,990
Net Income From Continuing Ops30,55930,559
Net Income49,519
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--1,188
 

Technical Analysis of Hunan Er Kang Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hunan Er Kang Pharmaceutical. The general trend of Hunan Er Kang Pharmaceutical is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hunan Er Kang Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hunan Er Kang Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.9326 < 3.0218 < 3.0218.

The bearish price targets are: 2.45 > 2.08.

Tweet this
Hunan Er Kang Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hunan Er Kang Pharmaceutical. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hunan Er Kang Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hunan Er Kang Pharmaceutical. The current macd is 0.01817504.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hunan Er Kang Pharmaceutical price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Hunan Er Kang Pharmaceutical. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Hunan Er Kang Pharmaceutical price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hunan Er Kang Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartHunan Er Kang Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hunan Er Kang Pharmaceutical. The current adx is 21.69.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hunan Er Kang Pharmaceutical shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Hunan Er Kang Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hunan Er Kang Pharmaceutical. The current sar is 2.472176.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Hunan Er Kang Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hunan Er Kang Pharmaceutical. The current rsi is 52.58. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Hunan Er Kang Pharmaceutical Daily Relative Strength Index (RSI) ChartHunan Er Kang Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hunan Er Kang Pharmaceutical. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hunan Er Kang Pharmaceutical price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hunan Er Kang Pharmaceutical Daily Stochastic Oscillator ChartHunan Er Kang Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hunan Er Kang Pharmaceutical. The current cci is 99.50.

Hunan Er Kang Pharmaceutical Daily Commodity Channel Index (CCI) ChartHunan Er Kang Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hunan Er Kang Pharmaceutical. The current cmo is 7.30101298.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Hunan Er Kang Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartHunan Er Kang Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hunan Er Kang Pharmaceutical. The current willr is -59.61538462.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hunan Er Kang Pharmaceutical is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hunan Er Kang Pharmaceutical Daily Williams %R ChartHunan Er Kang Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hunan Er Kang Pharmaceutical.

Hunan Er Kang Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hunan Er Kang Pharmaceutical. The current atr is 0.12924712.

Hunan Er Kang Pharmaceutical Daily Average True Range (ATR) ChartHunan Er Kang Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hunan Er Kang Pharmaceutical. The current obv is -201,468,863.

Hunan Er Kang Pharmaceutical Daily On-Balance Volume (OBV) ChartHunan Er Kang Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hunan Er Kang Pharmaceutical. The current mfi is 52.13.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Hunan Er Kang Pharmaceutical Daily Money Flow Index (MFI) ChartHunan Er Kang Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hunan Er Kang Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Hunan Er Kang Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hunan Er Kang Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.581
Ma 20Greater thanMa 502.618
Ma 50Greater thanMa 1002.667
Ma 100Greater thanMa 2003.025
OpenGreater thanClose2.740
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hunan Er Kang Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Hunan Er Kang Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hunan Er Kang Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hunan Er Kang Pharmaceutical

I send you an email if I find something interesting about Hunan Er Kang Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Hunan Er Kang Pharmaceutical.

Receive notifications about Hunan Er Kang Pharmaceutical in your mailbox!